The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 16, 2021

Filed:

Jun. 27, 2018
Applicants:

Vib Vzw, Ghent, BE;

Universiteit Gent, Ghent, BE;

Centre National DE LA Recherche Scientifique, Paris, FR;

Université DE Montpellier, Montpellier, FR;

Centre Hospitalier Regional Universitaire DE Montpellier, Montpellier, FR;

Universitat Osnabruck, Osnabrück, DE;

Inventors:

Jan Tavernier, Balegem, BE;

Gilles Uzé, Montpellier, FR;

Guillaume Cartron, Combaillaux, FR;

Franciane Paul, Montpellier, FR;

Jacob Piehler, Osnabrück, DE;

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 38/21 (2006.01); C07K 14/56 (2006.01); C07K 16/28 (2006.01); C07K 16/32 (2006.01); A61K 47/68 (2017.01);
U.S. Cl.
CPC ...
A61K 38/212 (2013.01); A61K 47/6813 (2017.08); C07K 14/56 (2013.01); C07K 16/2827 (2013.01); C07K 16/2863 (2013.01); C07K 16/2869 (2013.01); C07K 16/2878 (2013.01); C07K 16/32 (2013.01); C07K 2317/22 (2013.01); C07K 2317/569 (2013.01); C07K 2317/622 (2013.01); C07K 2319/31 (2013.01); C07K 2319/74 (2013.01);
Abstract

This disclosure relates to a modified α-helical bundle cytokine, with reduced activity via an α-helical bundle cytokine receptor, wherein the α-helical bundle cytokine is specifically delivered to target cells. Preferably, the α-helical bundle cytokine is a mutant, more preferably it is a mutant interferon, with low affinity to the interferon receptor, wherein the mutant interferon is specifically delivered to target cells. The targeting is realized by fusion of the modified α-helical bundle cytokine to a targeting moiety, preferably an antibody. This disclosure relates further to the use of such targeted modified α-helical bundle cytokine to treat diseases. A preferred embodiment is the use of a targeted mutant interferon, to treat diseases, preferably viral diseases and tumors.


Find Patent Forward Citations

Loading…